Synthetic tRNA Extended Anticodon Loop Nonsense Mutation Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for treating genetic diseases, such as cystic fibrosis, face challenges due to the short-lived nature of mRNA and the difficulty in delivering longer mRNA sequences using available vectors, while existing stop codon suppressor agents are often ineffective and poorly tolerated.
Innovation Solution
Development of synthetic transfer RNA (tRNA) with an extended anticodon loop capable of base-pairing with two consecutive codons on mRNA, including premature termination codons, to facilitate the incorporation of amino acids and restore functional protein synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If mRNA is used for gene therapy to replace defective genetic material, then the therapeutic effect can be achieved, but the mRNA is short-lived and longer sequences cannot be delivered using available vectors
Solution Approach 1:
The invention divides the long mRNA sequence into multiple shorter tRNA molecules, each capable of independent delivery and function. This segmentation allows the therapeutic genetic information to be delivered in manageable units that fit within vector capacity limits while collectively covering the entire target sequence.
Solution Approach 2:
The invention introduces tRNA molecules as intermediary carriers between the defective gene and the functional protein product. These tRNAs act as mediators that can suppress premature stop codons and facilitate readthrough, enabling the production of full-length functional proteins from mutated mRNA templates without requiring delivery of the entire corrected mRNA sequence.
2Reliability
If stop codon suppressor agents are used to promote translational readthrough, then functional CFTR can be recovered, but the agents are often neither effective nor well tolerated
Solution Approach 1:
The invention uses short-lived tRNA molecules as disposable therapeutic agents that temporarily suppress stop codons during translation. These tRNAs are naturally degraded after performing their function, avoiding the accumulation and long-term side effects associated with small molecule suppressor agents. The transient nature of tRNA action provides effective readthrough promotion without persistent toxic effects.
Data Source
AI summary
The invention relates to a synthetic transfer RNA with an extended anticodon loop. The invention provides a synthetic suppressor transfer RNA useful for the treatment of a genetic disease like cystic fibrosis associated with a nonsense mutation. The synthetic transfer RNA contains an extended anticodon loop with two consecutive anticodon base triplets configured to base-pair to two consecutive codon base triplets on an mRNA. The first anticodon base triplet or the second anticodon base triplet is configured to base-pair to a stop codon base triplet on the mRNA.